Expert Review of Neurotherapeutics最新文献_第3页

Managing sleep issues in Parkinson's disease: an up-to-date review. 帕金森病的睡眠问题管理：最新综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2025-01-10 DOI: 10.1080/14737175.2025.2450789

Keisuke Suzuki, Hiroaki Fujita, Saro Kobayashi

{"title":"Managing sleep issues in Parkinson's disease: an up-to-date review.","authors":"Keisuke Suzuki, Hiroaki Fujita, Saro Kobayashi","doi":"10.1080/14737175.2025.2450789","DOIUrl":"10.1080/14737175.2025.2450789","url":null,"abstract":"Introduction: In Parkinson's disease (PD), sleep-wake problems are disease-related symptoms that occur throughout the day and have a negative impact on patients' quality of life to an extent that is equal to or greater than that of typical motor symptoms.Areas covered: Insomnia due to fragmented sleep and excessive daytime sleepiness (EDS) worsen as PD progresses. Nighttime wearing-off and early morning-off should be considered first when fragmented sleep is reported in PD patients. If the main complaint of patients with insomnia is difficulty falling asleep, restless legs syndrome should be differentiated first. Obstructive sleep apnea causes sleep quality deterioration and fragmented sleep. For rapid eye movement sleep behavior disorder (RBD), preventative measures against sleep-related trauma are necessary. RBD has also attracted attention as a PD precursor state and as a disease progression marker that is associated with specific PD clinical subtypes. In PD patients, the sleep-wake phase may advance/delay or become irregular due to circadian dysfunction.Expert opinion: Importantly, sleep-wake problems are core symptoms related to the pathogenesis and progression of PD, and addressing a wide range of these symptoms will improve patients' quality of life.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"211-226"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The complexities in the differential diagnosis of restless legs syndrome (Willis-Ekbom disease). 不宁腿综合征（Willis-ekbom病）鉴别诊断的复杂性。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2025-01-14 DOI: 10.1080/14737175.2025.2450639

Karolina Poplawska-Domaszewicz, Silvia Rota, Mubasher A Qamar, K Ray Chaudhuri

{"title":"The complexities in the differential diagnosis of restless legs syndrome (Willis-Ekbom disease).","authors":"Karolina Poplawska-Domaszewicz, Silvia Rota, Mubasher A Qamar, K Ray Chaudhuri","doi":"10.1080/14737175.2025.2450639","DOIUrl":"10.1080/14737175.2025.2450639","url":null,"abstract":"Introduction: We present a literature review on the clinical conundrums surrounding the differential diagnosis of restless legs syndrome (RLS, Willis-Ekbom disease), as well as conditions that can mimic RLS. An extensive literature search showed that secondary causes of RLS ranged from commonly recognized causes, such as iron deficiency anemia, to less widely noted causes, such as rheumatoid disorders and hypothyroidism. There is a controversial association with Parkinson's disease, essential tremor, and RLS, whereby RLS is proposed as a prodromal feature.Areas covered: The clinical presentation of restless legs syndrome (RLS), a highly prevalent movement disorder usually during sleep with a circadian variation. The review highlights differences between commonly established secondary causes of RLS, RLS mimics, genetic and drug-induced RLS. A flowchart presents some key features of different and overlapping secondary RLS and mimics and genetic RLS.Expert opinion: RLS is one of the commonest movement disorders and the International Restless Legs Syndrome Study Group has suggested five-point criteria for robust diagnosis of RLS. However, even in expert hands, diagnosis is accurate in about 85% and misdiagnosis, especially with 'RLS mimics,' appears to be high. There are wide variations in the way RLS can present, and this includes different types of secondary RLS as well as drug induced or genetic patterns of RLS. Secondary RLS is highly complex and can be associated with Parkinson's disease as well as prodromal stage of Parkinson and essential tremor. Other known causes of secondary RLS are many and include end-stage kidney disease as well as metabolic disorders to painful conditions such as rheumatic disorders and fibromyalgia and polyradiculopathy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"157-173"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives. 体生长抑素类似物治疗神经内分泌肿瘤的现状和未来展望。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2024-10-16 DOI: 10.1080/14737175.2024.2417419

Eleonora Lauricella, Sofija Vilisova, Nada Chaoul, Andrea Giglio, Gabriella D'Angelo, Camillo Porta, Mauro Cives

{"title":"The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives.","authors":"Eleonora Lauricella, Sofija Vilisova, Nada Chaoul, Andrea Giglio, Gabriella D'Angelo, Camillo Porta, Mauro Cives","doi":"10.1080/14737175.2024.2417419","DOIUrl":"10.1080/14737175.2024.2417419","url":null,"abstract":"Introduction: Somatostatin analogs (SSAs) were developed as antisecretory agents to palliate hormonal symptoms in patients with functioning neuroendocrine tumors (NETs). Their antiproliferative activity has been established in the phase 3 PROMID and CLARINET trials. SSAs currently represent the standard first-line therapy for the majority of well-differentiated G1/G2 gastroenteropancreatic NETs as well as for pulmonary NETs.Areas covered: An update on the clinical applications of established SSAs for the treatment of NETs is provided. Perspectives on emerging nonpeptide SSAs such as paltusotine and innovative formulations of octreotide (CAM2029) are included.Expert opinion: SSAs represent the cornerstone of treatment for both functioning and nonfunctioning NETs. While standard-dose SSAs have a defined place in the therapeutic algorithm of well-differentiated NETs, uncertainties remain on how to best integrate above-label doses of SSAs in the treatment sequence, particularly when tumor control is the goal. Octreotide and lanreotide appear to be clinically interchangeable, and no signs of superiority of one agent over the other has been observed so far. Whether SSAs may be exploited in the maintenance setting following more aggressive treatments, whether continuing SSAs beyond-progression after first-line therapy could be an effective treatment strategy, and whether new-generation SSAs such as pasireotide could overcome resistance to established SSAs are key areas of investigation.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"245-258"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective. 评估致幻剂对精神医学的价值和风险：临床观点。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2024-12-23 DOI: 10.1080/14737175.2024.2445016

Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri, Gerardo Russomanno, Matteo Gambini, Anna Magnesa, Andrea Coccoglioniti, Giulio Perugi

{"title":"Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.","authors":"Donatella Marazziti, Francesco Weiss, Riccardo Gurrieri, Gerardo Russomanno, Matteo Gambini, Anna Magnesa, Andrea Coccoglioniti, Giulio Perugi","doi":"10.1080/14737175.2024.2445016","DOIUrl":"10.1080/14737175.2024.2445016","url":null,"abstract":"Introduction: After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during the last two decades. However, the resounding enthusiasm linked to such 'psychedelic renaissance' runs the risk to unduly minimize the possible hazards associated with these compounds, while expanding their alleged benefits to improbable panacea-like proportions. In order to avoid mystifying or demonizing the properties of 5-HT2a agonists on emotional grounds, this subject requires a strictly unprejudiced and cautious approach to the evidence.Areas covered: In this article, the authors attempted to comprehensively analyze the available literature to provide a balanced overview of the possible benefits of psychedelics in healthcare, taking into account their potential risks.Expert opinion: To date, psychedelics have shown a therapeutic potential in a wide range of conditions, with a seemingly limited risk of inducing adverse reactions, including abuse and dependence, when administered in a controlled environment by specialized personnel. In any case, although several questions remain unanswered before drawing firm conclusions, further studies are needed to establish which conditions and subjects could benefit from psychedelics and which patients bear the greater risk of adversities.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"143-156"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What are the main challenges in the treatment of neonatal hypoxic ischemic encephalopathy? 新生儿缺氧缺血性脑病治疗的主要挑战是什么？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2024-12-11 DOI: 10.1080/14737175.2024.2438649

Francesco Pisani, Carlotta Spagnoli

引用次数: 0

Managing cognitive impairment in Parkinson's disease: an update of the literature. 帕金森病的认知障碍管理：文献更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2025-01-10 DOI: 10.1080/14737175.2025.2450668

Jennifer G Goldman, Priya Jagota, Elie Matar

{"title":"Managing cognitive impairment in Parkinson's disease: an update of the literature.","authors":"Jennifer G Goldman, Priya Jagota, Elie Matar","doi":"10.1080/14737175.2025.2450668","DOIUrl":"10.1080/14737175.2025.2450668","url":null,"abstract":"Introduction: Cognitive impairment in Parkinson's disease (PD) substantially affects patient outcomes, function, and quality of life. PD-related cognitive dysfunction is often heterogeneous in clinical presentation and rates of progression. As cognitive changes occur in many people with PD, it is essential to evaluate cognition, provide education, and implement management strategies for cognitive symptoms.Areas covered: This article describes the symptomatology, epidemiology, risk factors, and pathobiology of cognitive impairment in PD. Additionally, the article provides an overview of evidence-based management and other therapeutic and coping strategies for cognitive impairment and dementia in PD. Comment is offered on challenges and opportunities for trials and emerging therapeutics targeting cognitive symptoms or decline.Expert opinion: While our understanding of cognitive dysfunction in PD has grown, effective and safe therapeutics are still needed to not only treat cognitive impairment and dementia symptomatically but also slow down or prevent cognitive decline. Further research is needed to elucidate the pathobiology of PD cognitive impairment, develop validated biomarkers reflecting cognitive change, and ultimately, integrate clinical and biological frameworks. Consensus regarding cognitive evaluations, definitions, and criteria of cognitive impairment, evaluating functional abilities in the context of cognitive impairment, and determining optimal outcome measures for clinical trials remain unmet needs.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"189-209"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the treatment and management of cognitive dysfunction in patients with multiple sclerosis. 多发性硬化症患者认知功能障碍的治疗和管理进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2025-01-16 DOI: 10.1080/14737175.2025.2450788

Ermelinda De Meo, Emilio Portaccio, Raffaello Bonacchi, Jasmine Giovannoli, Claudia Niccolai, Maria Pia Amato

{"title":"An update on the treatment and management of cognitive dysfunction in patients with multiple sclerosis.","authors":"Ermelinda De Meo, Emilio Portaccio, Raffaello Bonacchi, Jasmine Giovannoli, Claudia Niccolai, Maria Pia Amato","doi":"10.1080/14737175.2025.2450788","DOIUrl":"10.1080/14737175.2025.2450788","url":null,"abstract":"Introduction: Cognitive impairment (CI) occurs in 34-70% of multiple sclerosis (MS) patients, significantly impacting quality of life. CI can occur independently of physical disability, even in those with 'benign MS.' Cognitive deficits are heterogeneous, but common areas affected include processing speed, memory, and executive functions.Areas covered: A comprehensive literature search was conducted across databases such as PubMed and Google Scholar, using keywords like 'MS,' 'cognition,' and 'cognitive rehabilitation.' We focused on clinical assessment tools, emerging cognitive phenotypes, and both pharmacological and non-pharmacological treatments, including disease-modifying therapies and cognitive rehabilitation techniques.Expert opinion: Current evidence underscores the need for a multifaceted approach to managing CI in MS, incorporating emerging pharmacological treatments, cognitive rehabilitation strategies, and exercise programs. Future research should prioritize defining optimal training intensities, integrating therapies for sustained cognitive enhancement, and exploring neuromodulation and neuroimaging biomarkers within randomized controlled trials aimed at improving cognitive functioning in MS.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"227-243"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert guidance on the differential diagnosis of neuroleptic malignant syndrome. 神经安定剂恶性综合征鉴别诊断专家指导。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2024-10-18 DOI: 10.1080/14737175.2024.2417414

Laura Orsolini, Umberto Volpe

引用次数: 0

Therapeutic barriers for headache management: issues facing the global north and global south in 2024. 头痛管理的治疗障碍：2024年全球北方和全球南方面临的问题。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-10 DOI: 10.1080/14737175.2025.2450647

William David Wells-Gatnik, Paolo Martelletti

引用次数: 0

Neuromodulation as a therapeutic approach for post-traumatic stress disorder: the evidence to date. 神经调节作为创伤后应激障碍的治疗方法：迄今为止的证据。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-01-01 Epub Date: 2024-12-24 DOI: 10.1080/14737175.2024.2442658

Felicia Manocchio, Jordan Enepekides, Sean Nestor, Peter Giacobbe, Jennifer S Rabin, Matthew J Burke, Krista L Lanctôt, Maged Goubran, Ying Meng, Nir Lipsman, Clement Hamani, Benjamin Davidson

{"title":"Neuromodulation as a therapeutic approach for post-traumatic stress disorder: the evidence to date.","authors":"Felicia Manocchio, Jordan Enepekides, Sean Nestor, Peter Giacobbe, Jennifer S Rabin, Matthew J Burke, Krista L Lanctôt, Maged Goubran, Ying Meng, Nir Lipsman, Clement Hamani, Benjamin Davidson","doi":"10.1080/14737175.2024.2442658","DOIUrl":"10.1080/14737175.2024.2442658","url":null,"abstract":"Introduction: Post-traumatic stress disorder (PTSD) can have debilitating effects on quality of life, and conventional treatments show mixed results. Neuromodulation is emerging as a promising approach for treating PTSD. This review examines current neuromodulatory treatments for PTSD, and highlights methodologies, clinical outcomes, and gaps in the literature to help guide future research.Areas covered: A PubMed search identified 252 studies on PTSD and neuromodulation, of which 61 were selected for full review. These included 37 studies on repetitive transcranial magnetic stimulation (rTMS), 10 on transcranial direct current stimulation (tDCS),4 on deep brain stimulation (DBS) and 2 on focused ultrasound (FUS).Expert opinion: The present review supports the potential of neuromodulation to reduce PTSD symptoms. rTMS and tDCS targeting the dlPFC appear effective through modulating neural circuits involved in fear processing and conditioning, however, literature varies regarding efficacy of stimulation frequencies and hemispheric targets. DBS targeting the amygdala or subcallosal cingulate white matter tracts improves treatment of refractory PTSD with sustained benefits, while FUS may improve symptoms through targeted modulation of brain structures such as the amygdala, though this technique is in the early stages of exploration. Future research should refine established neuromodulatory approaches and address gaps in emerging modalities to enhance treatment efficacy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"101-120"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0